News

Industries

Companies

Jobs

Events

People

Video

Audio

Galleries

My Biz

Submit content

My Account

Advertise with us

New research shows how statins may cut risk of lethal prostate cancer

Men who are on statins to lower blood cholesterol may have a reduced risk of developing a more lethal form of prostate cancer, according to new research led by Queen's University Belfast.
Dr Emma Allott,
Dr Emma Allott,

The study, published in Clinical Cancer Research, was carried out by researchers at Queen’s University Belfast, Trinity College Dublin and the Dana-Farber/Harvard Cancer Center.

Previous studies have suggested that statins could have a role in slowing down the growth of different types of cancers. This research specifically looked at ways statins might affect prostate cancer.

The researchers discovered that there were no differences in the overall rates of prostate cancer among men who were prescribed statins. However, men who had taken statin medicines had a 24% reduced risk of developing a more lethal type of prostate cancer when compared to men who were not.

Lead author Dr Emma Allott, from the Centre for Cancer Research and Cell Biology and the Institute for Global Food Security at Queen’s University Belfast, said: “Some prostate cancers are slow growing and will not affect the man over the course of his lifetime, but others are aggressive and often deadly. My work is to understand the biology driving these different types of prostate cancer in order to reduce the number of men who develop this lethal form of the disease.

“By studying a large group of men who had been monitored for 24 years, we were able to see the link between statin use and the prevention of lethal prostate cancer. We then looked at tissue samples from some of these men to try and understand why the statin use was having this impact.

“Although the findings are at an early stage, we were able to see that statin use may affect inflammation and immunity levels in the prostates of some men as well as having an effect on the characteristics of the tumour itself. Our findings are in agreement with some of the known biology of statins but are the first to observe these effects in prostate cancer.”

Let's do Biz